Achieving tight glycaemic control without severe hypoglycaemia still shows a tangled task in insulin-treated diabetes.

Closed-loop artificial pancreas systems hold promise for reducing the burden of diabetes self-management, but there is still potential for improvement with regard to avoidance of both hypoglycaemia and hyperglycaemia.

In a recent study, researchers have found that Dasiglucagon offers the potential to provide rapid and reliable treatment of severe hypoglycemia.

• Brief Anger Hampers Blood Vessel Function Leading to Increased Risk of Heart Disease and Stroke – New Study
• New Blood Test Pinpoints Future Stroke Risk – Study Identifies Inflammatory Molecules as Key Biomarker
• Enceladus: A Potential Haven for Extraterrestrial Life in its Hidden Ocean Depths
• New Experiment: Dark Matter Is Not As ‘DARK’ As All We Think
• Scientists in Fear of This New Predator From Red Sea Eating Native Species in Mediterranean

Recently Dasiglucagon was approved by the US Food and Drug Administration for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and older based on the findings of this phase 3 trial.

Dasiglucagon is a potential first-in-class soluble glucagon analog invented and developed by Zealand Pharma. Dr Thomas R. Piebe and his team conducted a phase 3 trial to evaluate the efficacy and safety of dasiglucagon, a ready-to-use, next-generation glucagon analog in aqueous formulation for subcutaneous dosing, for treatment of severe hypoglycemia in adults with type 1 diabetes.

It was a randomized, double-blind trial of 170 adult participants with type 1 diabetes. The researchers randomly assigned the patients to receive a single subcutaneous dose of 0.6 mg dasiglucagon, placebo, or 1 mg reconstituted glucagon during controlled insulin-induced hypoglycemia.

The major outcome assessed was time to plasma glucose recovery, defined as an increase of ≥20 mg/dL from baseline without rescue intravenous glucose. The researchers compared dasiglucagon versus placebo; reconstituted lyophilized glucagon was included as a reference.

• FDA: Six people die during Pfizer vaccine trial
• Artificial Pancreas: what diabetics might expect in the future
• This food you eat every day increases the risk of developing diabetes

Key findings of the study were:

• Upon evaluation, the researchers found that the time to recovery was 10 minutes for dasiglucagon compared with 40 minutes for placebo; the corresponding result for reconstituted glucagon was 12 minutes.
• They noted that the participants in the dasiglucagon group achieved plasma glucose recovery within 15 min in all but one participant (99%), superior to placebo (2%) and similar to glucagon (95%).
• They observed similar outcomes for the other investigated time points at 10, 20, and 30 min after dosing.
• The most frequent adverse effects reported were nausea and vomiting, as expected with glucagon treatment.

The authors concluded:

• Brief Anger Hampers Blood Vessel Function Leading to Increased Risk of Heart Disease and Stroke – New Study
• New Blood Test Pinpoints Future Stroke Risk – Study Identifies Inflammatory Molecules as Key Biomarker
• Enceladus: A Potential Haven for Extraterrestrial Life in its Hidden Ocean Depths
• New Experiment: Dark Matter Is Not As ‘DARK’ As All We Think
• Scientists in Fear of This New Predator From Red Sea Eating Native Species in Mediterranean

The study findings were published in the journal Diabetes Care on April 21, 2021.

Image Credit: iStock